News & Updates

New guidelines: Paradigm shift in CV management of T2D patients

27 Sep 2024 by

Recently published cardiovascular outcome trials (CVOTs) in patients with diabetes (DM) have led to updates in the management of cardiovascular disease (CVD) in DM patients. These updates were reflected in the 2019 ESC guidelines on diabetes, prediabetes, and CVD, a collaboration between ESC and EASD*.

New guidelines: Paradigm shift in CV management of T2D patients

27 Sep 2024

Hypertension and the Asia Pacific region

18 Sep 2024 by

Cardiovascular disease remains one of the leading causes of mortality in the Philippines. Dr. Rafael Castillo, during his presidential lecture delivered at the 10th Asian-Pacific Congress of Hypertension last February 12 to 15 in Cebu City, likened hypertension to a storm surge. Every year, close to 120,000 Filipinos die due to complications related to hypertension. Non-optimal control of blood pressure imposes a huge socioeconomic burden as it causes disruption of work, family and social relationships.

Hypertension and the Asia Pacific region

18 Sep 2024

Hypertension and dementia: is there a link?

18 Sep 2024 by

The age at which one acquires hypertension may matter on the risk of dementia later on, with mid-life hypertension shown to be associated with late-life dementia.

Hypertension and dementia: is there a link?

18 Sep 2024

Dietary management to control hypertension

18 Sep 2024 by

Dietary Approaches to Stop Hypertension (DASH) is a highly effective aspect of the non-pharmacologic management of hypertension. Based on a research sponsored by the US-based National Heart, Lung and Blood Institute, it targets hypertensive as well as normotensive individuals at risk for hypertension.

Dietary management to control hypertension

18 Sep 2024

[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC

17 Sep 2024 by

Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.

[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC

17 Sep 2024

Can stem cells treat hypertension?

17 Sep 2024 by

With prominent personalities swearing by stem cells, physicians must keep a close eye on this novel treatment modality. During the 10th Asia-Pacific Congress of Hypertension, Dr. Eva Maria Cutiongco-dela Paz of the Philippine Genome Center and the Institute of Human Genetics at the National Institutes of Health brought physicians up to speed on the basic science on stem cells and how it may be applied to hypertension.

Can stem cells treat hypertension?

17 Sep 2024

Arginine depletion plus chemo ups survival in rare lung cancer

13 Sep 2024 by

In the pivotal phase II/III ATOMIC-Meso* trial, adding the first-in-class, arginine-depleting agent pegargiminase to standard first-line platinum-pemetrexed chemotherapy prolongs overall survival (OS) and progression-free survival (PFS) in patients with treatment-naïve, nonresectable, nonepithelioid pleural mesothelioma.

Arginine depletion plus chemo ups survival in rare lung cancer

13 Sep 2024

BP measurements, while not always reliable, still yield valuable information

12 Sep 2024 by

Blood pressure measurements, in spite of their potentially variable and unreliable nature, provide valuable information about cardiovascular disease and other complications of high blood pressure (BP), said an expert from Australia.

BP measurements, while not always reliable, still yield valuable information

12 Sep 2024

Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE

11 Sep 2024 by

The triplet combination of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is as good as dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in terms of efficacy for HIV control but results in better hepatitis B virus (HBV) outcomes in patients with HIV/HBV co-infection, according to results of the phase III ALLIANCE trial presented at IAS 2022.

Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE

11 Sep 2024

Dupilumab benefits in kids with asthma hold out to 52 weeks

26 Aug 2024 by

Dupilumab significantly continues to improve lung function — including measures of the large and small airways — out to 52 weeks in children with uncontrolled, moderate-to-severe asthma, according to 52-week data of the LIBERTY ASTHMA VOYAGE trial.

Dupilumab benefits in kids with asthma hold out to 52 weeks

26 Aug 2024

News & Updates

Filter by Specialty:

Specialty:

New guidelines: Paradigm shift in CV management of T2D patients

New guidelines: Paradigm shift in CV management of T2D patients

Hypertension and the Asia Pacific region

Hypertension and the Asia Pacific region

Hypertension and dementia: is there a link?

Hypertension and dementia: is there a link?

Dietary management to control hypertension

Dietary management to control hypertension

[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC

[test headline bait]Amivantamab plus chemo tied to better outcomes in NSCLC

Can stem cells treat hypertension?

Can stem cells treat hypertension?

Arginine depletion plus chemo ups survival in rare lung cancer

Arginine depletion plus chemo ups survival in rare lung cancer

BP measurements, while not always reliable, still yield valuable information

BP measurements, while not always reliable, still yield valuable information

Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE

Trial of two tenofovir-containing regimens for HIV/HBV co-infection: Insights from ALLIANCE

Dupilumab benefits in kids with asthma hold out to 52 weeks

Dupilumab benefits in kids with asthma hold out to 52 weeks